Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
LICR SITES
New Melbourne Branch Director Sought
Dr. Antony W. Burgess, AC, Founding Director of the LICR's largest Branch, has announced that he will step down as Director in April 2009. The new Director of the LICR Melbourne Branch will have the opportunity to be a key opinion leader in both the LICR's global laboratory and clinical research programs and in Australia's cancer research community. Applications are now being sought for Director of the LICR Melbourne Branch. Read more here
News
June 22, 2008
Leukemia drug could save lives of stroke patients
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. After that, tPA may cause dangerous bleeding in the brain. However, in a study published today in Nature Medicine, investigators from the Stockholm Branch of the Ludwig Institute for Cancer Research (LICR) and the University of Michigan show that these problems might be overcome if tPA is combined with the leukemia drug, imatinib (Gleevec®).
May 5, 2008
New Player in Colon Cancer Genesis Identified
In a study published today in Cancer Cell, a group led by LICR Affiliate Dr. Kari Alitalo (Helsinki, Finland), identified the PROX1 protein as a key driver of colon cancer tumorigenesis.